In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS), an ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Hims stock soared 12% today and was trading at $56.00 at press time. Trading volume was way up, and the stock’s been on a ...

Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the ...

Hims & Hers Health ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the ...

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no ...

Shares of Hims Hers Health Inc (NYSE:HIMS) fell more than 3% early Tuesday before paring losses to around 0.2% in afternoon trade, after rising legal risks and a data disclosure drove swings in ...

Hims & Hers Health, Inc. HIMS has seen a surge in retail investor interest, which positions it as one of the most ...

Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million ...

The stock has continued falling since that article came out last month, so I wanted to follow up. Hims & Hers announced its GLP-1 launch on May 20, 2024.

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision to end a partnership for Wegovy. Read more here.

U.S. equities were higher at midday as concerns oil prices would spike because of the U.S. attack on Iran diminished.